Approved IND for Alligator Bioscience’s CD40-targeting antibody mitazalimab
Lund, Sweden, December 4, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an approved IND (Investigational new Drug) for the CD40 targeting antibody mitazalimab. IND approval by the US Food and Drug Administration (FDA) is a prerequisite to start clinical trials in the USA. Recently, new benchmark data was published showing that mitazalimab has the potential to be best-in-class in the CD40 field. The comparison demonstrated the potent immune-activating properties and anti-tumor effects of mitazalimab. “While the upcoming clinical Phase Ib/II study in pancreatic